Objectives: Thymidine kinase 1 (TK1) is one of the salvage enzymes engaged in the synthesis of DNA. Although a pro-carcinogenetic role of TK1 has been reported in various types of cancers, its role in pancreatic ductal adenocarcinoma (PDAC) is still unknown. The study is aimed to elaborate the function of TK1 in PDAC and the potential mechanisms in the following study.
| INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive digestive malignancies and is the fourth most common cause of cancer-related death in the United States. Patients diagnosed with PDAC have a poor prognosis with an overall 5 year survival rate of only 8% and a median survival of 6 months.
1 Although the morbidity of this malignant tumour has been increased over the last several years, there is no obvious improvement in the survival rate. Surgical resection may prolong survival and provide a unique curative option. Unfortunately, the surgical resection rate is <20% because of difficulty for diagnosis at early stage. 2 Therefore, an increasing understanding of the complex molecular basis of PDAC and exploring novel therapeutic targets may contribute to the clinical treatment of this aggressive malignancy.
Thymidine kinase 1 (TK1), a cell cycle-dependent marker, is a pyrimidine salvage enzyme involved in the synthesis and repair of DNA.
Thus, TK1 is closely correlated with cell proliferation and cell cycle activity. 3, 4 It is reported that wide distribution and overexpression of TK1 are found in most neoplastic cells. clinicopathological predictive markers in various types of cancers like breast cancer, 6 kidney cancer, 7, 8 lung cancer, 9 and gastrointestinal cancer; 10 however, little has been explored about the expression and biological function of TK1 in PDAC. To further identify the role of TK1
in PDAC, we evaluated the expression patterns in PDAC cell lines and tissues and investigated the possible molecular mechanism.
| MATERIALS AND METHODS

| Tissue microarray
This study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. TK1 mRNA expression of 165 patients with pancreatic cancer was downloaded from
The Cancer Genome Atlas (TCGA, USA) data portal (http://cancergenome.nih.gov/). Seventy-two pancreatic cancer tissues and matched adjacent tissues microarray were obtained from Shanghai Zhuoli Biotechnology Co., Ltd (Zhuoli Biotechnology Co, Shanghai, China).
All tissue samples applied in this study were fixed in formalin, embedded paraffin and further used for IHC.
| Immunohistochemical staining and analysis
Formalin-fixed paraffin-embedded tissues were sliced into 5 μm thickness, and then deparaffinized with xylene, and gradually rehydrated in grated ethanol solutions. Next, the slides were incubated with the anti-TK1 antibody (1:150; Abcam, Cambridge, MA, UK) at 4°C overnight, followed by incubation with biotinylated goat anti-rabbit serum streptavidin-peroxidase conjugate at room temperature for 30 minutes. Finally, the sections were developed with diaminobenzidine and counterstained with haematoxylin. Two independent pathologists who were blinded to assess the positivity and intensity of the tissue sections. The percentage of TK1-positive staining cells was scored as 0 (0%), 1 (1%), 2 (2%) … 99 (99%), 100 (100%). The staining intensity was given 0 (none), 1 (low), 2 (medium) and 3 (high) scores, respectively. A combination of the two scores was calculated by the following formula for all cases: IHC score = positive rate score × intensity score. supplemented with 10% foetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 .
| Cell lines and cell culture
| Transfection of small interfering RNA
The siRNA and the scrambled negative control of TK1 and E2F-1 used in this study were synthesized and purchased from GenePharma (Shanghai, China). The siRNA and the scrambled negative control sequences were as follows: TK1 siRNA#1, 5′-GG UG AUCAAGUAUGCCAAATT-3′ (sense) and The efficiency of all siRNAs was detected by qRT-PCR and Western blot. 
| Western blot analysis
| Proliferation assay
| Cell proliferation assay
The PDAC cells were seeded into 96 well plates at a density of 2.5 × 10 3 cells per well after co-incubation with siRNA for TK1. 10 μL of Cell Counting Kit-8 reagent (Dojindo, Tokyo, Japan) and 100 μL complete medium were mixed and added to each well to detect the cell viability. After incubation in dark at 37°C for 3 hours, each well was analysed at 450 nm absorbance.
| Clone formation assay
Human pancreatic cancer cell lines treated with or without siRNA of TK1 were plated at a density of 1 × 10 3 cells/well in 6 well plates.
Cells were cultured for 10 days in DMEM supplemented with 10% FBS, penicillin (100 U/mL) and streptomycin (100 μg/mL) in a 37°C
humidified atmosphere of 5% CO 2 . The colonies were stained with crystal violet solution, and then the number was counted.
| Cell cycle analysis
PANC-1 and CFPAC-1 cells were harvested after transfection of siRNA for TK1 and negative controls for 72 hours and fixed with 70%
ethanol overnight at 4°C, and then incubated with 500 μL PI/RNase staining buffer at 37°C for 15 minutes. Cell cycle was analysed by flow cytometer (Gallios, Beckman Coulter, Brea, CA, USA).
| Apoptosis detection
Pancreatic ductal adenocarcinoma cells were harvested after transfection for 48 hours and resuspended in 500 μL Annexin V binding buffer. 5 μL PE Annexin V and 7-AAD Viability Staining Solution were used to stain tumour cells. After incubation in dark at room temperature for 15 minutes, cells were analysed by flow cytometer (Gallios, Beckman Coulter).
| Transwell assay
Cell migration and invasion were respectively performed using 
| Wound-healing assay
Wound-healing assays were performed in 6 well plates to assess cell migration. A scratch was made 24 hours after transfection. The cells were then cultured in serum-free DMEM for 24 hours. To assess migrated cells and wound area, pictures were taken at 0, 12 and 24 hours.
| Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) was carried out with the Magna Chromatin Immunoprecipitation kit (Millipore, Darmstadt, Germany).
Immunoprecipitations were performed with anti-E2F-1 antibodies.
ChIP products and genomic input DNA were analysed by qRT-PCR 
| Animal studies
| Statistical analysis
| RESULTS
| Expression of TK1 in PDAC
Generally, expression of TK1 mRNA in PDAC tissues (n = 165) was observed based on the data provided by TCGA ( Figure 1A) . The correlation between TK1 expression and the clinicopathologic characteristics in PDAC from all 165 patients in TCGA were shown in Table 1 . It was shown that high level of TK1 was significantly correlated with higher T staging and positively correlated with Ki67 expression ( Figure 1F ).
Furthermore, the Kaplan-Meier survival curves showed that PDAC patients with high level of TK1 have a shorter survival ( Figure 1D ,E).
Cox proportional hazard regression model suggested that TK1 was an independent prognostic factor for PDAC patients (Table 2) .
To further detect the TK1 protein expression in PDAC, 72 pancreatic cancer tissues and matched adjacent tissues were analysed, which revealed that protein levels of TK1 were significantly higher in cancerous tissues compared to that in adjacent non-cancerous tissues ( Figure 1B,C) . We also analysed the association between TK1 expression and clinicopathological characteristics in these patients, and TK1
overexpression was correlated with the TNM stage and histological grade (Table 3) .
| Knockdown of TK1 expression by siRNA
TK1 expression was also measured in five PDAC cell lines (MiaPaCa-2, SW1990, BxPc-3, CFPAC-1 and PANC-1) and a normal human pancreatic ductal cell line (hTERT-HPNE) by qRT-PCR and Western blot.
Compared to hTERT-HPNE, TK1 expression was higher in all cancer cell lines (Figure 2A,B) . CFPAC-1 and PANC-1 were chosen to further study due to the relatively higher expression of TK1. CFPAC-1
and PANC-1 were used to conduct siRNA-related assays. The interference efficiency of three siRNAs (labelled as siRNA#1, siRNA#2
and siRNA#3) was detected at both mRNA and protein levels.
siRNA#3 with the highest efficiency was chosen for further studies ( Figure 2C,D) .
| Effects of gene silencing of TK1 on cell proliferation, apoptosis and cell cycle
We supposed that TK1 played a vital role in the proliferation of PDAC cells because of its correlation with Ki67. Therefore, CCK-8 and clone formation assays were performed to investigate the effect of TK1 on PDAC cell proliferation. As shown in Figure Figure 4C , downregulation of TK1 induced an increased cell percentage in S phase compared to control group. These results indicated that interference of TK1 could suppress PDAC cell proliferation by S phase arrest.
Western blot was used to further examine the effect of downregulation of TK1 on the expression of cell cycle and apoptotic related proteins. Several proteins (cyclin A, cyclin B1, cyclin D1, cyclin E, CDK2, CDK4, CDK1, P21, P27 which might play a fundamental role in S phase) were further assessed by Western blot. It has been proven that Cyclin E and CDK2 could regulate normal S phase progression, 13,14 and we found downregulation of TK1 decreased the expression levels of cyclin E and CDK2 and increased the expression of P21.
The result indicated that downregulation of TK1 in PDAC cells may induce S phase arrest by upregulating P21.
| Downregulation of TK1 exhibit no effect on migration and invasion
We conducted migration and invasion assay in vitro to explore the effects of TK1 knockdown on migration and invasion of PDAC cells. As shown in Figure S1 , downregulation of TK1 had no impact on migration and invasion of PDAC cells. The result was also confirmed by detecting the key proteins involved in migration and invasion of cancer cells with Western blot (Figure S1 ).
| Expression of TK1 was directly regulated by E2F-1
As an essential gene involved in DNA replication and synthesis, it is reported that TK1 was directly regulated by E2F-1 in several studies.
15-18
To find out whether E2F-1 regulates the TK1 transcription in PDAC cells, Figure 5C ). Furthermore, the proliferation of PDAC cells was inhibited after E2F-1 knockdown ( Figure 5D ). These results suggested that E2F-1 might directly regulate the transcription of TK1 to further affect the cell proliferation in PDAC cells.
| DISCUSSION
In this study, we have identified high expression of TK1 was tightly correlated with the progression and prognosis of PDAC. In addition, E2F-1 could directly regulate TK1 transcription and promote PDAC cell proliferation. As far as we know, this study first identified aggressive characters of TK1 in PDAC, which suggested that TK1 could function as a prognostic and therapeutic target for PDAC.
It was generally known that plentiful oncogenes and complex mechanisms played a vital role in development and progression of PDAC. TK1 was a type of TK which plays a significant role in mammalian cell cycle due to its vital function in DNA replication and repair.
Increasing activity of TK1 during S phase could promote cell cycle from S phase to G2/M phase. 19 TK1 was overexpressed in mitotic or malignant cells, but absent in quiescent cells. [20] [21] [22] Lots of studies have focused on the diagnostic and prognostic value of TK1 in many tumours. 23 Mao et al 6 discovered the application of TK1 as a cell proliferation marker in human breast cancer. Kruck et al 8 observed that
high TK1 expression has been described to be associated with a higher stage, and grade in renal cell carcinoma. Moreover, TK1 has been assessed as a marker for prediction of biochemical recurrence in prostate cancer. 24 However, the expression pattern and function of TK1 in PDAC are not elucidated. In this study, relationship between TK1 expression and patient characteristics analysis indicated that high-TK1 expression correlated with Ki67, higher T stage (from TCGA data statistics), and advanced tumour stage (from IHC data statistics).
We also observed that overexpression of TK1 in PDAC was associated with a shorter OS time and DFS time of PDAC patients. Further analysis identified that TK1 was an independent risk factor for poor prognosis.
Furthermore, we found that downregulation of TK1 could inhibit cell proliferation in vivo and in vitro, and the mechanisms involved in this phenomenon were still unclear. Cell cycle and apoptosis were confirmed to be involved in the process of proliferation. 25,26 Therefore, we
Effects of gene silencing of thymidine kinase 1 (TK1) on apoptosis and cell cycle. A, B, There was no statistical difference on the percentage of apoptotic cells and apoptosis-related proteins between two groups. C, D, Western blot indicated increased P21 was responsible for S phase arrest which was induced by TK1 knockdown. * represents P < .05, and ** represents P < .01
supposed that whether these processes contribute to the proliferation of PDAC cells. Although no obvious changes were observed in apoptosis, S phase arrest was observed in PDAC cells by TK1 knockdown. We found that the inhibition of S phase was concomitant with decreased CDK2, cyclin A and cyclin E expressions in TK1 knockdown PDAC cell, as well as increased P21 expression. P21, known as an inhibitor of the cyclin-dependent kinase, could inhibit the activation of CDK1, CDK2
and CDK4. [27] [28] [29] [30] TK1 might interact with P21 by combining with the C-terminal domain of P21. 31 Our data showed that CDK2 was obviously downregulated after interfering TK1; however, CDK1 and CDK4 expressions might not be affected by the change of TK1. PDAC cell cycle arrest after TK1 downregulation might be mediated by P21/
CDK2 interaction.
No evidence has shown that overexpression of TK1 was correlated with blood vessel invasion in clinicopathologic characteristics of PDAC patient. Accordingly, migration, invasion and Western blot assays further proved that there was no relation between TK1 overexpression and migration or invasion of PDAC cells.
We have identified the downstream genes regulated by TK1, and the upstream regulatory factors for TK1 were further investigated in our study. E2F-1, as an important transcription factor, is required for timely control of plentiful genes involved in DNA replication, repair and cell cycle. 15 The previous study has reported that E2F-1 could directly bind to the promoter of TK1. [15] [16] [17] [18] We also confirmed that E2F-1 was an upstream regulatory gene of TK1 in PDAC. Furthermore, there were some other factors that could regulate TK1, including C-MYC, 32 FHIT, 33 SP1 34 and Prohibition, 17 which might relate to potential pathways and involved in regulation of TK1. Further studies should be designed to explore the mechanism of TK1 in PDAC.
To the best of our current knowledge, this study first revealed the overexpression of TK1 in PDAC. Abnormal expression of TK1 is associated with progression of PDAC and a poor prognosis of PDAC patients. Downregulation of TK1 impedes PDAC proliferation both in vitro and in vivo experiments. As a transcription factor, E2F-1 could directly mediate expression of TK1. Therefore, TK1 could serve as a new anti-cancer target for treating PDAC.
